Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 13Breast Neoplasms, Male 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Intraductal, Noninfiltrating 2Recurrence 1Pancreatic Cyst 1Osteosarcoma 1Inflammatory Breast Neoplasms 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Carcinoma In Situ 1Brain Neoplasms 1Advanced Cancer 1

Interventions

Cyclophosphamide 14Gemcitabine 6Filgrastim 6fludarabine 5Methotrexate 5Leucovorin 5Granulocyte Colony-Stimulating Factor 5Zoledronic Acid 4Temozolomide 4Mesna 4Irinotecan 4Ifosfamide 4Etoposide 4Cisplatin 4Carboplatin 4pembrolizumab 3fludarabine phosphate 3Doxorubicin 3Biopsy 3tanespimycin 2poly ICLC 2pegfilgrastim 2lorukafusp alfa 2liposomal doxorubicin 2dinutuximab 2cabozantinib 2belinostat 2Topotecan 2Thalidomide 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Osteosarcoma × Tamoxifen × Clear all
NCT00001436 2008-03-04

A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
24 enrolled
Sarcoma

Neoplasm Metastasis, Recurrence, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡